SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC
作者: Man YuanLin-feng XuJuan ZhangSi-yuan KongMan WuYuan-zhi LaoHua ZhouLi ZhangHongxi Xu Hongxi Xu
刊名: Frontiers in Oncology, 2019, Vol.9
来源数据库: Directory of Open Access Journals
DOI: 10.3389/fonc.2019.00586
关键词: Non-small-cell lung cancerMEK and SRC inhibitorTrametinibBosutinibSynergistic effect
原始语种摘要: Non-small-cell lung cancer (NSCLC) is the predominant form of lung cancer, and it is regulated by a complex signal transduction network. Single-agent targeted therapy often results in acquired resistance, which leads to treatment failure. In this study, we demonstrated that a combination of the kinase inhibitors trametinib and bosutinib can synergistically suppress the growth of NSCLC by inhibiting both the mitogen-activated protein kinase (MAPK) and proto-oncogene tyrosine-protein kinase (SRC) pathways. The combination was profiled against a panel of 22 NSCLC cell lines, including one erlotinib-resistant cell line, and this combination was found to show synergistic effects against 16 cell lines. NSCLC cell lines (HCC827, HCC827-erlotinib-resistant, and H1650) were treated with...
全文获取路径: DOAJ  (合作)

  • combination 聚形
  • resistant 耐久的
  • kinase 激酶
  • Cancer 巨蟹座
  • inhibition 抑制
  • tumor 肿胀
  • regulated 规定
  • protein 蛋白质
  • findings 结论
  • targeted 对准目标的